NovaBay Pharmaceuticals (NYSE:NBY) Trading Down 4.3% – Should You Sell?

NovaBay Pharmaceuticals, Inc. (NYSE:NBY)’s stock price dropped 4.3% during mid-day trading on Thursday . The stock traded as low as $0.70 and last traded at $0.72. Approximately 312,994 shares were traded during mid-day trading, a decline of 70% from the average daily volume of 1,027,167 shares. The stock had previously closed at $0.75.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on NovaBay Pharmaceuticals in a report on Friday. They set a “hold” rating for the company.

NovaBay Pharmaceuticals Trading Up 4.7 %

The business has a 50 day moving average of $0.59 and a two-hundred day moving average of $1.75. The firm has a market cap of $3.67 million, a P/E ratio of -0.01 and a beta of 0.75.

NovaBay Pharmaceuticals (NYSE:NBY) last announced its earnings results on Tuesday, August 13th. The company reported ($1.37) EPS for the quarter. The company had revenue of $2.40 million for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 744.33% and a negative net margin of 91.86%. On average, sell-side analysts predict that NovaBay Pharmaceuticals, Inc. will post -1.41 EPS for the current year.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.